Drugs / rHPIV1 84/del170/942A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00641017 | Mar 2008 → Jul 2012 | parainfluenza infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHPIV-1/84/del 170/942A | “rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and...” PMID 26582883 ↗ Nov 2014 |
| Modality | Vaccine | “experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine” PMID 26582883 ↗ Nov 2014 |
| Route | Intranasal | “administered intranasally via nose drops at study entry” NCT00641017 ↗ |